fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Amgen Contemplates Further Issuance of Green Bonds- $AMGN $DIA

By John F. Heerdink, Jr.

Reportedly, Pharmaceutical giant Amgen Inc. (AMGN) is planning to sell more bonds to benefit the environment and society after its debut green bond was received well by investors. Amgen raised $4 billion in February in a four-part transaction including a $750 million green-bond tranche, a first for Amgen. The component was six times over-subscribed by a diverse portfolio of investors, informed Judy Brown, senior vice-president of corporate affairs. Companies are under immense pressure from regulators and investors to slash their carbon emissions and are rushing to issue debt linked to environmental, social, or governance projects to grow their ESG credentials.

“We had, I’m very proud to say, very robust interest from the market. That’s a win-win and it creates a competitive market,” stated Judy Brown, senior vice-president of corporate affairs.
 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.

(Read Original Story: Amgen Mulls More Green Bonds After ‘Robust Interest’ in Debut in Bloomberg)


YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us